Conavi Medical Uplists to OTCQB Venture Market
- Expected to enhance visibility and access to U.S. investors
- Trading to commence soon
TORONTO — Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF), a pioneering medical device company, recently announced its uplisting to the OTCQB Venture Market, a significant milestone for the firm. By transitioning from the previous OTC Pink Open Market, the company aims to improve transparency for U.S. investors. This strategic move is in conjunction with the upcoming launch of their innovative Novasight Hybrid™ System, which is designed to assist in minimally invasive cardiovascular procedures.
CEO Thomas Looby expressed enthusiasm about this transition, stating, "We’re pleased to increase investor transparency and visibility with this uplisting,” highlighting the potential for expanding their investor base and market presence.
The OTCQB Market: A Gateway to Growth
Operating under the OTC Markets Group, the OTCQB is recognized as an established public market that caters to developing and entrepreneurial-stage companies. This marketplace offers companies the opportunity to access capital effortlessly while enhancing their visibility to investors. Additionally, companies listed on the OTCQB adhere to higher reporting standards, ensuring that they maintain current information. This uplisting is expected to further solidify Conavi Medical’s commitment to its stakeholders.
Anticipated Impact of Uplisting
The uplisting is projected to broaden the reach of Conavi Medical among U.S. investors, potentially attracting more attention to its cutting-edge technologies. By being listed on the OTCQB, Conavi is in a better position to establish credibility and facilitate its growth trajectory. As they work towards launching the Novasight system, this increased investor interest could be crucial for securing necessary partnerships and capital required for expansion.
Innovative Technology at the Forefront
Conavi Medical specializes in the development of advanced imaging technologies that aim to transform cardiovascular procedures. Their flagship product, the Novasight Hybrid™ System, stands out as a revolutionary tool that combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for comprehensive imaging. This pioneering approach allows healthcare professionals to gain accurate insights into coronary arteries, revolutionizing the way cardiac interventions are performed.
Regulatory Approvals and Market Readiness
The Novasight Hybrid System has already received 510(k) clearance from the U.S. Food and Drug Administration, along with approvals from other significant regulatory bodies, including Health Canada and China’s National Medical Products Administration. These accomplishments not only underline the sophistication of Conavi's technology but also position the company favorably in the competitive market of medical devices.
Future Prospects and Shareholder Confidence
Investors can look forward to a more robust Conavi Medical as it embarks on this new chapter with the uplisting to the OTCQB. With a solid foundation of regulatory support and innovative products on the horizon, the company is well-poised for success. The leadership at Conavi remains optimistic that this step will not only enhance their market presence but also provide increased confidence to existing and prospective shareholders.
Contact Information
For any inquiries, please reach out to:
Stefano Picone
Chief Financial Officer
ir@conavi.com
(416) 483-0100
Frequently Asked Questions
1. What does the uplisting to OTCQB mean for Conavi Medical?
The uplisting enhances visibility and access to U.S. investors, promoting growth opportunities for the company.
2. How does the Novasight Hybrid System work?
The system combines IVUS and OCT technologies to provide simultaneous imaging of coronary arteries for improved diagnostic insights.
3. Which regulatory bodies have approved Conavi’s products?
Conavi’s Novasight Hybrid System has received approvals from the U.S. FDA, Health Canada, and regulatory authorities in China and Japan.
4. When can investors expect trading to start on OTCQB?
Trading on the OTCQB Venture Market is expected to commence shortly after the uplisting announcement.
5. Who can investors contact for more information?
Investors can contact Stefano Picone, CFO, via email at ir@conavi.com.
